Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

checkpoint inhibitor

- PMLiVE

MSD’s Keytruda catches up in kidney cancer

Combination therapy approved in EU for all risk groups

- PMLiVE

AZ, Merck’s Lynparza scores market-expanding clinical success

Positive phase 3 findings in ovarian cancer

- PMLiVE

Keytruda now available for untreated metastatic lung cancer patients via Cancer Drugs Fund

Proves continuing dominance in this indication

- PMLiVE

Keytruda scores in neoadjuvant triple negative breast cancer combo

Tecentriq still in pole position

Bristol Myers Squibb logo

Opdivo trial overshadows BMS financial results

Hope remains in Celgene merger

- PMLiVE

NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

Acknowledges unmet need

- PMLiVE

Merck says it has plenty in the pipe beyond Keytruda

It has the firepower, but is Merck seeking a big deal?

- PMLiVE

Keytruda begins pursuit of rivals in small cell lung cancer

Set for competition with Opdivo

- PMLiVE

Is our health at risk by delaying Dr appointments?

It’s Cervical Screening Awareness week 10-16 June, so now is the perfect time to check when your last appointment was.

Page & Page and Partners

- PMLiVE

Research charity LifeArc cashes $1.2bn royalty from Keytruda

UK medical research charity pledges to expand its work

- PMLiVE

Keytruda monotherapy fails in triple negative breast cancer

Fails in gambit to outflank rival Tecentriq

- PMLiVE

Bad news for BMS as Keytruda kidney cancer combo approved

Opdivo and Yervoy combination will be squeezed

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links